18F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study

International Journal of Urology

Volumn 20, Issue 8, 2013, Pages 788-796

  Hitier Berthault, Maryam ^a   Ansquer, Catherine ^a   Branchereau, Julien ^a   Renaudin, Karine ^b   Bodere, Françoise ^a   Bouchot, Olivier ^a   Rigaud, Jérôme ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

18F fluorodeoxyglucose positron emission tomography computed tomography; Bladder cancer; Computed tomography; Cystectomy; Lymph node; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; BLADDER CANCER; COMPUTED TOMOGRAPHY; CYSTECTOMY; LYMPH NODE; STAGING;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CYSTECTOMY; FLUORODEOXYGLUCOSE F18; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MULTIMODAL IMAGING; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 84881311806     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12045     Document Type: Article

References (30)

1. Pfister C, Roupret M, Wallerand H etal. Recommandations en Onco-Urologie 2010: tumeurs urotheliales. Prog. Urol. 2010; 20 (Suppl 4): S255-274.
2. Stenzl A, Cowan NC, De Santis M etal. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol. 2011; 59: 1009-1018.
3. Braud G, Battisti S, Karam G, Bouchot O, Rigaud J. Valeur pronostique du curage ganglionnaire lors des cystectomies totales pour cancer de la vessie. Prog. Urol. 2008; 18: 351-357.
4. Zerbib M, Bouchot O. Envahissement ganglionnaire pN+ et cystectomie totale. Prog. Urol. 2002; 12: 931-939.
5. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol. 2000; 163: 1693-1696.
6. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 2005; 48: 189-199; discussion 99-201.
7. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 2005; 48: 202-205; discussion 205-6.
8. Hatanaka M. Transport of sugars in tumor cell membranes. Biochim. Biophys. Acta 1974; 355: 77-104.
9. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe A 1999; 38: 46-50.
10. Zehnder P, Studer UE, Skinner EC etal. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J. Urol. 2011; 186: 1261-1268.
11. Zlotta AR. Limited, extended, superextended, megaextended pelvic lymph node dissection at the time of radical cystectomy: what should we perform? Eur. Urol. 2012; 61: 243-244.
12. Jensen JB, Ulhoi BP, Jensen KM. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int. J. Urol. 2012; 19: 39-47.
13. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur. J. Nucl. Med. 1997; 24: 615-620.
14. Liu Y, Ghesani NV, Skurnick JH, Zuckier LS. The F + 0 protocol for diuretic renography results in fewer interrupted studies due to voiding than the F - 15 protocol. J. Nucl. Med. 2005; 46: 1317-1320.
15. Kamel EM, Jichlinski P, Prior JO etal. Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J. Nucl. Med. 2006; 47: 1803-1807.
16. Koyama K, Okamura T, Kawabe J etal. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. J. Nucl. Med. 2003; 44: 353-358.
17. Picchio M, Treiber U, Beer AJ etal. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J. Nucl. Med. 2006; 47: 938-944.
18. Maurer T, Souvatzoglou M, Kubler H etal. Diagnostic efficacy of [11C]Choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur. Urol. 2012; 61: 1031-1038.
19. Babjuk M, Oosterlinck W, Sylvester R etal. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 2011; 59: 997-1008.
20. Sherif A, De La Torre M, Malmstrom PU, Thorn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J. Urol. 2001; 166: 812-815.
21. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J. Nucl. Med. 2001; 42 (5 Suppl): 1S-93S.
22. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J. Nucl. Med. 2003; 44: 1301-1314.
23. Apolo AB, Riches J, Schoder H etal. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J. Clin. Oncol. 2010; 28: 3973-3978.
24. Liu IJ, Lai YH, Espiritu JI etal. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol. Int. 2006; 77: 69-75.
25. Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010; 106: 658-663.
26. Lu YY, Chen JH, Liang JA etal. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur. J. Radiol. 2012; 81: 2411-2416.
27. Heicappell R, Muller-Mattheis V, Reinhardt M etal. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur. Urol. 1999; 36: 582-587.
28. Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 1412-1417.
29. Kibel AS, Dehdashti F, Katz MD etal. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J. Clin. Oncol. 2009; 27: 4314-4320.
30. Swinnen G, Maes A, Pottel H etal. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur. Urol. 2010; 57: 641-647.